$AMGN

HR8032 ensures equitable Medicare payment for cancer treatments, directly benefiting pharmaceutical companies and biotech firms focused on oncology. This bill stabilizes revenue streams for cancer drug manufacturers within the outpatient setting.

The Advancing Education on Biosimilars Act of 2021 increases awareness and adoption of biosimilar drugs, directly benefiting biosimilar manufacturers and increasing competition for branded biologic drug companies. This legislation expands the market for biosimilars and drives down healthcare costs.

The Immediate Access for the Terminally Ill Act accelerates patient access to experimental treatments, directly benefiting pharmaceutical and biotechnology companies developing late-stage therapies. This bill expands the market for investigational drugs, increasing revenue potential for companies with promising pipelines.

The Immediate Access for the Terminally Ill Act accelerates patient access to experimental drugs, increasing revenue opportunities for pharmaceutical companies with late-stage clinical pipelines. This bill directly expands the market for investigational therapies by reducing regulatory hurdles.

The Treat and Reduce Obesity Act of 2025 expands Medicare coverage for obesity treatments, directly benefiting pharmaceutical companies producing GLP-1 agonists and medical device manufacturers. This legislation significantly increases the total addressable market for these therapies.

The 'Skinny Labels, Big Savings Act' directly targets brand-name pharmaceutical companies by limiting their ability to block generic competition. This legislation will reduce drug prices and significantly decrease revenue for innovator drug manufacturers, while benefiting generic drug producers.